ReviewInternational journal of cancer2021
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.
Review in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years.Frontiers in oncology · 2024Pooled it
- Diffuse Hepatic, Splenic, and Osseous Activity Due to Multiple Myeloma.Clinical nuclear medicine · 2026Article
- Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future Directions.Cancers · 2026Review
- Clinical and laboratory characteristics and management in patients diagnosed with multiple myeloma: real-world cohort in a Peruvian referral clinic.Ecancermedicalscience · 2026Article
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- HERV-K Envelope Induce a Humoral Response in Non-Hodgkin Lymphoma Patients.Current microbiology · 2025Article
- Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.Scientific reports · 2025Article
- Visual presentation of age differences in relative survival of hematological neoplasms in Sweden and the neighboring countries.Annals of hematology · 2025Article
- TRIM44 facilitates aggressive behaviors in multiple myeloma through promoting ZEB1 deubiquitination.Discover oncology · 2025Article
- Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis.Journal of translational medicine · 2025Article
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
- Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns.Advances in hematology · 2025Article
- Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential.Frontiers in immunology · 2025Review
- Comprehensive analysis of plasma cell heterogeneity and immune interactions in multiple myeloma.Frontiers in immunology · 2025Article
- Trends in mortality rates associated with multiple myeloma in the United States, 1999-2023.Frontiers in oncology · 2025Article
- Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis.Acta pharmaceutica Sinica. B · 2024Article
- The risk and survival of multiple myeloma as the second primary malignancy in a single Chinese center.Translational cancer research · 2024Article
- Article
- The numerous facets of 1q21Oncology letters · 2024Review
- Beyond the mouth: Uncovering non-secretory multiple myeloma through oral symptoms.Imaging science in dentistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 people being diagnosed with MM per year. Whereas 5-year survival after a diagnosis of MM has improved from 28% in 1975 to 56% in 2012, the disease remains essentially incurable. In this review, we summarize our current understanding of MM including its epidemiology, genetics and biology. We will also provide an overview of MM management that has led to improvements in survival, including recent changes to diagnosis and therapies. Areas of unmet need include the management of patients with high-risk MM, those with reduced performance status and those refractory to standard therapies. Ongoing research into the biology and early detection of MM as well as the development of novel therapies, such as immunotherapies, has the potential to influence MM practice in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.